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Summary Serial CA125 measurements in 169 patients with epithelial ovarian carcinoma were obtained.
Changes in serum CA125 measurements are shown to reflect changes in clinical status. For patients with
macroscopic disease receiving chemotherapy, the sensitivity and specificity for predicting response are shown
to be 95% and 86% respectively. For patients with no known disease, the sensitivity and specificity for
detecting relapse are shown to be 86% and 91% respectively. The clinical correlates with the level of serum
CA125 were examined and the most important is shown to be amount of residual disease.
CA125 is the antigen recognised by the monoclonal antibody,
OC125, produced by immunising BALB/c mice with a cell
line OVCA 433 cultured from the ascitic fluid of a patient
with a papillary serous cystadenocarcinoma of the ovary and
using somatic hybridisation of the spleen cells with a mouse
myeloma (Bast et al., 1981). Initially it was thought to be
specific for ovarian malignancy (Bast et al., 1981; Kabawat et
al., 1983a) of the serous, endometrioid and clear cell types
but it was subsequently shown to be a high-molecular-weight
glycoprotein expressed on coelomic epithelium during emb-
ryonic development (Kabawat et al., 1983b).
As multiple antigenic determinants are present on each
molecule of the protein an immunoradiometric assay for free
serum CA125 was developed (Klug et al., 1984). Using this,
normal values have been determined and it has also been
established that CA125 values are raised in the serum of
patients with a variety of other malignancies (Klug et al.,
1984); in particular mucinous carcinoma of the ovary (Can-
ney et al., 1984) and gastrointestinal malignancies (Haga et
al., 1986a). CA125 is also found to be raised in a variety of
benign conditions including pregnancy, pelvic inflammatory
disease (Haga et al., 1986b; Halila et al., 1986) and cirrhosis
(Bergmann et al., 1987). In view of this the exact origin of
the antigen is uncertain and it has recently been suggested
that CA125 may be a marker of ascites (Bergmann et al.,
1987) or non-specific peritoneal damage (Redman et al.,
1988).
Unfortunately it would appear that CA125 is neither spe-
cific enough nor sensitive enough to be used alone as a
screening test for early carcinoma of the ovary (Heinonen et
al., 1985). It has been shown, however, that CA125 is useful
in the monitoring of patients undergoing treatment for car-
cinoma of the ovary (Bast et al., 1983; Canney et al., 1984;
Heinonen et al., 1985) as the change in level of antigen is
correlated well with response status.
We set out here to determine how effective CA125 is in a
routine clinical setting for: (a) predicting responses in patients
with macroscopic disease undergoing chemotherapy, (b) pre-
dicting relapse in patients with no known disease and (c)
which of the clinical factors - residual disease, stage, ascites
and histological type - are the main correlates of CA125.
Patients and methods
Patients with ovarian cancer had serum CA125 measure-
ments taken on a routine basis at outpatient appointments
and on admission. In general CA125 was measured monthly
on patients undergoing chemotherapy and two/three-monthly
in those patients being followed up but not on active treat-
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ment. The assay used was a standard commercially available
kit (Compagnie Oris Industrie) - results of the assay were not,
however, available to those treating the patients and were not
used in the assessment of responses or management of the
disease.
The data presented are those collected over an 18-month
period. CA125 measurements on 1632 samples from 389
patients were made but only those patients with epithelial
ovarian carcinoma who had four or more CA125 measure-
ments were analysed further. This amounted to 1220 mea-
surements in 169 patients.
Initial data recorded for each patient was collected at
diagnostic laparotomy or last major operation or scan re-
view. The initial data recorded was stage (FIGO, 1976),
amount of residual tumour, amount of ascites and histo-
logical type. These initial data are shown in Table I. At each
follow-up visit the following data were entered: amount of
ascites, last treatment given and response to that treatment.
The majority of patients were in one of several studies and
were assessed in detail, although inevitably those patients
with bulk resistant disease were investigated less since the
treatment options were limited. Response was assessed clin-
ically at each visit and by CT. and/or ultrasound imaging
after at least every third course of treatment and by lapar-
otomy or laparoscopy, if indicated, at the completion of
chemotherapy.
Response to treatment was assessed as partial response
(PR), complete response (CR), progressive disease (PD) or no
change (NC), according to WHO criteria. In analysing the
data for response CR and PR are combined as 'response' and
NC and PD combined as 'no response'.
Those patients who were stage I at presentation were
followed by 6-monthly laparoscopy and those not on active
treatment were investigated as clinically indicated. Response
assessed on the basis of CA125 was based on a doubling
being progressive disease and halving as disease response (65
Table I Patient characterisation
Histology Residual
Mucinous 22 Nil 57
Serous 99 <2cm 34
Endometrioid 25 2- 5 cm 33
Clear cell 9 >5 cm 39
Undiff. adeno. 14 Uncertain 6
Stage Ascites
1 18 Nil 110
11 4 Small/trace 10
III 42 Moderate/large 37
IV 23 Uncertain 12
Previously treated
No disease (CR) 34
Disease - on treatment 18
Disease- no treatment 30
Total number of patients 169
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was taken as the minimum from which response could be
accurately measured).
Correlation of CA125 measurements with various factors
was examined initially using univariate methods and x2 tests.
To try to identify the most important correlates further
factor analysis was carried out using multiple linear regres-
sion performed with the standard MINITAB program. In the
linear regression model the following coding was used -
CA125 (<35 Um[l-=0, 35-65Uml-'=1, 65-130 U-
ml-'=2, 130-250Uml-'=3, 250-50 OUml-'=4, >500
Uml-'=5), residual (<2cm=0, 2-5 cm=l, >5cm=2),
stage (III = 0, IV = 1), ascites (nil = 0, small = 1, moderate/
large = 2), histology (as stated in results section).
Results
Monitoring ofpatients with macroscopic disease during
treatment
There were 89 patients who had adequate assessment of
response by clinical methods and had CA 125 measurements
at appropriate times to detect response. They had been
treated mainly with platinum compounds (Table II) with
eight patients receiving more than one treatment regimen so
that there were 97 treatments received. Patient response was
assessed clinically as stated and on each occasion where a
clinical response was apparent the response as assessed by
serial CA125 measurement was determined. Fifteen patients
were not assessable using CA125, 14 because the level was
too low and one because the level was always over
500 U ml-'. Of the 14 with low levels most had small
residual disease but some had bulk residual disease and may
be considered truly antigen negative. Four of the 14 with low
levels subsequently had elevated serum CA125 but 10 had
low levels throughout the follow-up period. The histological
types of those tumours not assessable using CA125 did not
differ significantly from the overall distribution (data not
shown). It was possible to assess response by both methods
on 88 occasions. The overall results are shown in Table III
and there is excellent agreement between the two methods.
There were nine patients in whom CA125 levels did not
correlate with clinical response. Two responded clinically but
the CA125 remained unchanged. They both had very tran-
sient clinical responses which lasted less than two months. Of
the seven who were thought to respond using CA125 but not
clinically, one had only a transient fall of CA125 level and a
later clinical assessment produced agreement of no response.
There were two in whom a 'differential response' occurred
(that is, regression of pelvic disease but progression ofdisease
elsewhere). The remaining four all had bulky progressive
disease.
In general we change (or stop) treatment if no response
occurs after an adequate trial of therapy. Sometimes, how-
Table 11 Treatments received
Platinum drugs alone 62
Alkylating agent alone 5
Platinum/alkylator combination 6
Mitozantrone 14
Trimelamol 9
Surgery I
Total 97
Table III Patients with macroscopic disease - CA125 and response
Clinical
CA125 No response Response Total
No response 44 2 46
Response 7 35 42
Total 51 37 88
Sensitivity = 35/37 = 0.95; predictive value + ve = 35/42 = 0.83; spe-
cificity = 44/51 = 0.86; predictive value -ve = 44/46 = 0.96.
ever, stable disease is a useful end-point; when all three
categories (response, no change, progressive disease) are con-
sidered overall agreement occurs in 63 out of 88 (72%)
events assessable by both methods.
Monitoring ofpatients with no known disease
There were 73 patients with satisfactory assessment by both
clinical methods and CA125 measurement: of these 23 were
monitored after initial surgery, 16 of which were stage I,
while 50 were in clinical and radiological CR after previous
treatment. Again the overall agreement was excellent, as
shown in Table IV. Of the two patients who relapsed clin-
ically but not using CA125, one was found at a follow-up
laparoscopy to be cytology positive only but one was found
on clinical examination to have a small recurrence at the
vault of the vagina; this was confirmed at laparatomy and
was the only disease identified. Of the five who relapsed using
CA125 but not clinically one had a transient rise in CA125
(only on one occasion was the CA125 level >65 Uml' but
it rose gradually over 4 months and then fell again spon-
taneously, eventually both CA125 and clinical status sugges-
ting that the patient remained in CR. A further three who
had relapsed using CA125 but not clinically by the end of the
study subsequently relapsed (up to 6 months later); only one
still has an elevated CA125 (level>300 Uml-1') 12 months
later and yet remains clinically well with no sign of recur-
rence.
In general CA125 measurement gave a moderate lead time
in predicting relapse so that in the 12 who had relapsed on
both methods the mean lead time was approximately 2
months for CA125 (median one month).
Factors associated with a raised CA125
Univariate analysis suggested that amount of residual dis-
ease, stage, amount of ascites and histology were correlated
with CA125 (data not shown). For histology the coding
which gave the best correlation was 1 = mucinous, 2 = un-
differentiated adenocarcinoma, 3 = endometrioid, 4 = serous
(clear cell omitted as there were so few). In order to try to
elucidate this further, since these factors are likely to be
interrelated, we carried out a multivariate analysis using a
standard forward selection method.
The results in Table V are given for newly diagnosed
patients with macroscopic disease at initial surgery (46 pa-
tients) and then for all patients, including those who have
Table IV Monitoring of patients with no known disease
Clinical
CA125 No change Relapse Total
No change 54 2 56
Relapse 5 12 17
Total 59 14 73
Sensitivity = 12/14 = 0.86; predictive value + ve = 12/17 = 0.71; spe-
cificity = 54/59 = 0.91; predictive value -ve = 54/56 = 0.96.
Table V Linear regression results
Regression P value P value
Factor coefficient univariate multivariate
Newt patients (with known disease present-stage 3/4)
Residual 0.473 <0.001
Stage 0.281 0.06
Ascites 0.202 n.s.
Histology 0.074 n.s.
Total number of patients 46
<0.001
n.s.
n.s.
n.s.
Pretreated andnewt patients (with known disease present-stage 3/4 and
relapse)
Residual 0.342
Ascites 0.279
Histology 0.148
Total number of patients 85
<0.01
<0.02
n.s.
<0.01
<0.05
n.s.636 R.E. HAWKINS et al.
Table VI CA125 by amount of residual disease (surgically assessed)
CA125 level (Uml-')
Residual <65 >65 Total % positive
Nil 12 2 14 14
<2cm 6 7 13 54
2-5 cm 2 10 12 83
> 5 cm 1 20 21 95
Total 21 39 60 65
Table VII CA125 by amount of ascites
CA125 level (U/mlt')
Ascites <65 65-250 >250 Total
None 252 50 59 361
Small 13 22 15 50
Moderate/large 7 13 35 55
Total 272 85 109 466
had previous therapy but who have macroscopic disease at
initial surgical/radiological assessment (85 patients). It is ap-
parent that for both sets of patients the amount of residual
disease is the most important factor correlating with CA125
measurement. For new patients no other factor adds to the
correlation after residual disease is allowed for although
stage initially appeared to be of some significance. When
previously treated patients are included (more have bulky
disease and ascites) then ascites comes out as a second
important independent factor correlating with CA125 mea-
surement. In neither analysis is histology an important fac-
tor.
Since amount of residual disease is shown to be the most
important correlate of serum CA125 it is useful to see how
often CA125 is usefully elevated (taken as over 65 so that a
response can be reliably detected): this is shown in Table VI
for surgically assessed patients (46 with macroscopic disease,
14 with no disease); similar data for amount of ascites (as
determined by scan) are shown in Table VII.
Discussion
We confirm previous studies (Bast et al., 1983; Canney et al.,
1984; Heinonen et al., 1985) that CA125 measurements are a
sensitive and specific way of monitoring patients undergoing
treatment for ovarian cancer and that of the order of
80-90% should be assessable by this means. Further analysis
of patients in whom conventional monitoring did not agree
with CA125 showed two problem groups of patients; those
had a differential response and those who had bulk residual
disease and high levels of serum CA125. There are several
factors that could account for the latter group: (1) The
clinical assessment of these patients may be less accurate as
many are treated with less intensive measurement of tumour
as the overall response is poor. CA125 may or may not
therefore be more accurate. (2) High level 'hook' effects may
occur as the samples were assayed at only one dilution. (3)
Some tumours may grow out with clones negative for
CA125.
Hook effects seem likely to only be a very occasional
problem as in the CA125 assay a serum level of over 20,000
U ml' (data on file CIS(UK)) must be reached before the
apparent level falls below 500 U ml-' and this is rare (none
out of 101 patients in Bast et al. (1983)). It is possible that
the overall usefulness could be improved if dilutions were
carried out so that levels above 500 U ml' could be mea-
sured. We have no data on the other possibilities.
Following patients in CR or stage I patients compared
favourably with our current methods of follow-up using CT
and ultrasound scans and more rarely laparoscopy or lap-
arotomy; this was also shown by Niloff et al. (1986). There
were two patients who relapsed clinically but not on CA125
and it cannot be determined whether or when CA125 mea-
surement would have detected the relapse as treatment was
commenced immediately; apart from these patients CA125
generally gave a lead over clinical relapse although in most
cases this was not very long. It may be that the lead time
could be improved if CA125 was measured more frequently;
in this study CA125 was only measured when patients came
up for other assessments but CA125 could easily be moni-
tored more frequently.
The multiple regression analysis suggests that the amount
of residual disease is the most important correlate of CA125.
In new patients after diagnostic laparotomy residual disease
is the only significant correlate although stage appears to be
the next most important correlate. When previously treated
patients, who in general have larger amounts of residual
disease and ascites, are included (stage not applicable) the two
independently significant correlates are the amount of resi-
dual disease and the amount of ascites. Overall we suggest
that it is the extent of disease that is the most important
factor in determining CA125 level although an additional
independent effect of ascites cannot be ruled out by our
analysis. Certainly the analysis suggests that ascites is not the
major determining factor for serum CA125, as was suggested
by Bergmann et al. (1987). It seems appropriate that residual
disease is an important factor since this is a major prognostic
factor and, in combination with stage, may be considered to
give an overall estimate of the amount of disease present.
When stage is not applicable (relapse patients) the presence
of ascites may be considered to be an alternative indicator of
widespread disease and thus in combination with residual
disease again to give a rough measure of total disease pres-
ent.
The origin of the measured CA125 is uncertain (Bergmann
et al., 1987). In addition to direct production by tumour cells
another possible site of antigen production is reactive meso-
thelial cells in the peritoneum (or pleura) since using sensitive
techniques (Kabawat et al., 1983b) these are shown to exp-
ress surface CA125. This site of origin is suggested by Berg-
mann et al. (1987) because of their evidence of raised levels
in cirrhosis, especially with ascites, and because it was shown
by Heinonen et al. (1985) that the level of antigen in the
ovarian vein of patients with ovarian carcinoma is little
different to that in a peripheral vein. This site of production
is also favoured by the fact that non-specific insults to the
peritoneum such as laparotomy may elevate the serum
CA125 (Redman et al., 1988). Fleuren et al. (1987) suggest
an alternative hypothesis that the peritoneum acts as a bar-
rier between the CA125 produced by the tumour and the
circulation and it is only when that is breached by malignant
infiltration that the serum CA125 becomes elevated. Perhaps
a combination of all these possibilities may occur. We have
no direct data on the possible origin of CA125 and either
origin would be consistent with our data as the amount of
disease also tends to reflect the amount of involved peri-
toneum (and pleura). Further experimental evidence would
be necessary to elucidate this.
This study confirms that CA125 is a sensitive and specific
means of monitoring patients with ovarian carcinoma. Com-
bined with other studies it suggests that in those patients who
have an elevated level after surgery CA125 could be used as
the major means of monitoring therapy until the CA125
reaches normal levels. At that stage it cannot be assumed
that there is no disease present and other methods of moni-
toring must be used. If the CA125 fails to reach normal
levels, or rises after falling, a switch to alternative treatment
is indicated if a useful alternative is available. Similarly those
who achieve CR or who have stage I disease could be
followed primarily with CA125 measurement. Treatment
should be considered if CA125 begins to rise without other
explanation (e.g. cirrhosis, peritoneal inflammation).
Strategies such as those suggested above are strikingly
similar to those used so effectively in the treatment of tera-
tomas using alpha-fetoprotein as a tumour marker. If further
study of serial CA125 levels confirm these results then fewer
unpleasant and expensive scans may need to be done.CLINICAL CORRELATES OF SERUM CA125 637
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